Systematic Biopsy of the Prostate Can Be Omitted in Men With PI-RADS™ 5 and PSA Density >15 | PracticeUpdate
Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate | Scientific Reports
Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy‐naive men: A prospective evaluation of the PLUM cohort - Patel - 2022 - Cancer - Wiley Online Library
Prostate Imaging-Reporting and Data System (PI-RADS) | Radiology Reference Article | Radiopaedia.org
A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS® Score and Ethnicity in a Diverse, Multiethnic Population | Journal of Urology
Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer | Radiology
Gallium 68 PSMA-11 PET/CT Imaging in Patients with PI-RADS 3 | Journal of Nuclear Medicine
The basics of PI-RADS scoring and how AI can help
PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? - ScienceDirect
Diagnostics | Free Full-Text | Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with
Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy | Journal of Urology
MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? - Schoots - Translational Andrology and Urology
Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions | Scientific Reports
JCM | Free Full-Text | New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions
What is PI-RADS and why should you care? | THE "NEW" PROSTATE CANCER INFOLINK
PI-RADS 3 Lesions: Does the Association of the Lesion Volume with the Prostate-Specific Antigen Density Matter in the Diagnosis of Clinically Significant Prostate Cancer? - Beyond the Abstract
PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? - ScienceDirect
The Radiology Assistant : Prostate Cancer - PI-RADS v2
Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer | Radiology
Prostate Imaging-Reporting and Data System (PI-RADS) | Radiology Reference Article | Radiopaedia.org
Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital | SpringerLink
MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? | Semantic Scholar
Prostate MRI based on PI-RADS version 2: how we review and report | Cancer Imaging | Full Text
Analysis of PI-RADS 4 cases_ Management recommendations for negatively biopsied patients
Frontiers | New TRUS Techniques and Imaging Features of PI-RADS 4 or 5: Influence on Tumor Targeting
